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A few days of bed rest or immobilization following injury, disease, or surgery can lead to con-
siderable loss of skeletal muscle mass and strength. It has been speculated that such short,
successive periods of muscle disuse may be largely responsible for the age-related loss of
muscle mass throughout the lifespan.
Objective
To assess whether a single intramuscular injection of nandrolone decanoate prior to immo-
bilization can attenuate the loss of muscle mass and strength in vivo in humans.
Design, setting and participants
Thirty healthy (22 ± 1 years) men were subjected to 7 days of one-legged knee immobiliza-
tion by means of a full leg cast with (NAD, n = 15) or without (CON, n = 15) prior intramuscu-
lar nandrolone decanoate injection (200 mg).
Measures
Before and immediately after immobilization, quadriceps muscle cross-sectional area (CSA)
(by means of single-slice computed tomography (CT) scans of the upper leg) and one-leg-
ged knee extension strength (one-repetition maximum [1-RM]) were assessed for both legs.
Furthermore, muscle biopsies from the immobilized leg were taken before and after immobi-
lization to assess type I and type II muscle fiber cross-sectional area.
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Results
Quadriceps muscle CSA decreased during immobilization in both CON and NAD (-6 ± 1%
and -6 ± 1%, respectively; main effect of time P<0.01), with no differences between the
groups (time × treatment interaction, P = 0.59). Leg muscle strength declined following
immobilization (-6 ± 2% in CON and -7 ± 3% in NAD; main effect of time, P<0.05), with no
differences between groups (time × treatment interaction, P = 0.55).
Conclusions
This is the first study to report that nandrolone decanoate administration does not preserve
skeletal muscle mass and strength during a short period of leg immobilization in vivo in
humans.
Introduction
Muscle disuse, such as forced upon following injury or during illness, can lead to substantial
loss of skeletal muscle mass and strength and has numerous negative side effects. Most periods
of muscle disuse tend to be of short duration, generally less than 7 days [1, 2]. Recently, it has
been shown that even a few days of muscle disuse can lead to a substantial decline in both mus-
cle mass as well as muscle strength [3]. It has been speculated that such short successive peri-
ods of bed rest or immobilization may be responsible for the greater part of muscle mass that
is lost throughout the lifespan [1, 4]. Obviously, effective exercise, nutritional and/or pharma-
ceutical strategies are required to prevent or attenuate skeletal muscle loss during such short,
successive periods of muscle disuse [5].
Skeletal muscle maintenance largely depends on the presence of two main anabolic stimuli,
dietary protein intake and physical activity [6]. Maintenance of some level of physical activity
is required to allow skeletal muscle mass preservation. However, this is not always possible in
case of disease, injury, and/or acute hospitalization. Furthermore, during a short period of bed
rest or immobilization, energy intake generally becomes compromised. As a consequence, die-
tary protein consumption is temporarily lowered thereby accelerating muscle loss [7]. Previous
work has shown that maintaining habitual dietary protein intake will attenuate muscle loss [4,
8–11], but protein supplementation well above habitual protein intake levels does not preserve
muscle mass during limb immobilization [12]. Therefore, adjuvant pharmaceutical interven-
tions may be useful in preserving muscle mass during short periods of bed rest or limb
immobilization.
Skeletal muscle disuse is accompanied by a decline in basal, post-absorptive muscle protein
synthesis rates, an increase in protein breakdown, and the development of anabolic resistance
to feeding [1, 13]. The anabolic androgenic steroid nandrolone, with nandrolone decanoate
as one of its esters [14–17], has been shown to increase protein synthesis and decrease proteol-
ysis [18, 19]. Prolonged nandrolone decanoate administration (ranging from 200–2400 mg for
a period between 1–24 months) has been shown to increase fat free mass, muscle cross-sec-
tional area (CSA) and/or strength in several pathological conditions in vivo in humans [20–
32]. Based on these findings it could be speculated that nandrolone decanoate administration
may represent an effective adjuvant pharmaceutical strategy to prevent or attenuate disuse
atrophy.
Therefore, the objective was to assess whether a single intramuscular injection of nandro-
lone decanoate prior to immobilization can attenuate the loss of muscle mass and strength in
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vivo in humans. We hypothesize that intramuscular administration of a single dose of nandro-
lone decanoate attenuates muscle mass and strength loss during subsequent leg immobiliza-
tion. To test this hypothesis we selected 30 healthy adults who were subjected to 7 days of one-
legged knee immobilization. One group (n = 15) received a single intramuscular nandrolone
decanoate injection (200 mg) immediately prior to immobilization, whereas the other group




Thirty young (18–35 years) healthy males (18.5< body mass index (BMI) < 30 kg/m2) partici-
pated in this experiment between October 2014 and April 2016 (Fig 1). Participants’ character-
istics are presented in Table 1. All subjects were screened and excluded in case one or more of
the following criteria were met: a history of thromboembolic events, smoker, history of partici-
pating in regular resistance type exercise training, back/leg/knee/shoulder complaints that
could interfere with the use of crutches, systematic use of corticosteroids, anabolic androgenic
steroids, growth hormone, immunosuppressants, insulin, or blood glucose lowering medica-
tion, pre-existing renal disease or potential risk for renal dysfunction (diabetes, hypertension,
reduced glomerular filtration rate), liver disease, heart failure or migraines. The study was per-
formed as part of a greater project in which we also investigated the impact of creatine and leu-
cine supplementation on muscle mass loss [33]. The sample size calculation was based upon
an expected >40% difference in the decline in quadriceps CSA following immobilization fol-
lowing nandrolone treatment (NAD) when compared to the control group. This would trans-
late to a ~3% decline in leg muscle CSA loss in the NAD group compared to a ~5% decline in
the control group. Taking into consideration drop-out rate of 10% during the experimental
trial, the final number of participants who had to be included per group was 15. All partici-
pants were informed about the purpose of the study, the experimental procedures, and all its
possible risks prior to providing written consent to participate. This study was approved by the
Medical Ethics Committee from the Maastricht University Medical Centre+ (MUMC+),
where the measurements took place. The procedures followed were in accordance with the
ethical standards of the responsible institutional committee on human experimentation and in
accordance with the Declaration of Helsinki of 2013.
Experimental outline
Eligible subjects were exposed to 7 days of muscle disuse induced by means of a full leg cast, as
described previously (2). Subjects allocated to the NAD group (n = 15) were administered 200
mg nandrolon-17β-decanoate (Deca-Durabolin, Aspen Pharma, Dublin, Ireland) by intramus-
cular injection in the gluteus maximus muscle after the baseline measurements, prior to cast-
ing. A comparison was made with a control group. Data from the CON group have been
published previously (NIH Clinical Trial Registration Number: NCT01894737) [33]. Study
procedures were identical for both NAD and CON group: the immobilized leg was randomly
allocated and counter-balanced between left and right. Two days prior to casting and directly
after cast removal, a series of measurements were performed. Single-slice computed tomogra-
phy (CT) scans of the upper leg were performed for both legs, muscle biopsies from the immo-
bilized leg and venous blood samples were collected, and one-legged knee extension strength
(one-repetition maximum [1-RM]) was assessed for both legs. All analyses were performed by
investigators blinded to subject coding.
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Pretesting/ Screening
Body weight, height, blood pressure, and heart rate were measured. Subsequently, subjects’
single-leg 1-RM strength was assessed as described previously [34, 35] on a leg extension
machine (Technogym, Rotterdam, The Netherlands). On the evening prior to both test days,
subjects received a standardized meal containing 2.9 MJ providing 51 energy% (En%) as car-
bohydrate, 32 En% as fat and 17 En% as protein. Subjects were asked to maintain their habitual
food intake during the study and to refrain from consuming alcohol in the 48 hours leading up
Fig 1. Flowchart of participants.
https://doi.org/10.1371/journal.pone.0210823.g001
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to a test day. All volunteers refrained from exhaustive physical activity from 48 hours prior to
the first test until the end of the study.
Limb immobilization protocol
Two days after the first test day, subjects reported at 0800 h at the casting room at MUMC+, to
have a full leg cast fitted. The application of the cast signified the first day of the 7-day immobi-
lization period. The casting procedure has been described previously [3, 34]. In short, the cir-
cular leg cast extended from 10 cm above the ankle to ~25 cm above the patella. The knee was
casted at a 30˚ angle of flexion to prevent subjects performing any weight bearing activities
with the casted leg. Subjects were provided with crutches for proper ambulation. Throughout
the immobilization period subjects were further advised to continue their normal physical
activity patterns where possible, but exclude any exhaustive physical activities (such as sports
activities). A physical therapist instructed all subjects how to walk the stairs safely. All subjects
were instructed to perform a series of simple ankle exercises (i.e. plantar and dorsal flexion,
and circular movements of the entire foot) to keep the calf muscle pump activated in the
immobilized leg, thereby minimizing the risk of developing deep vein thrombosis. After 7 days
of immobilization and prior to the start of the second test day, subjects visited the casting
room again to have the cast removed. Thereafter, subjects were transferred by wheelchair to
perform the CT scan and collect the muscle biopsy prior to any weight bearing activities.
Muscle mass, muscle biopsies, blood sampling and strength
Subjects participated in two identical experimental test days, before and immediately after the
immobilization period. Approximately 2 days prior to the immobilization period, subjects
arrived at the laboratory at 0800 h in an overnight fasted state, and body weight was measured
with a digital balance with an accuracy of 0.1 kg (SECA GmbH, Hamburg, Germany). Thereaf-
ter, a single-slice CT scan (Philips Brilliance 64; Philips Medical Systems, Best, The Nether-
lands) was performed to assess quadriceps muscle and upper leg muscle anatomical CSA in
both legs. The scanning characteristics were as follows: 120 kV, 300 mA, rotation time of 0.75
seconds and a field of view of 500 mm. With subjects lying supine with their legs extended and
feet secured, a 3 mm thick axial image was taken 15 cm proximal to the top of the patella. The
precise scan position was marked with semi-permanent ink for the 7 days of immobilization to
ensure accurate repeat measurements at the second test day. Muscle area of the immobilized
leg was selected between -29 and 150 Hounsfield units, after which the quadriceps muscle was
selected by manual tracing using ImageJ software (version 1.46d; National Institute of Health,
Bethesda, MD, USA) [36].
Table 1. Subjects’ characteristics.
CON (n = 13) NAD (n = 15)
Age (y) 23 ± 1 22 ± 1
Body mass (kg) 73.1 ± 3.2 71.3 ± 2.4
Height (m) 1.76 ± 0.03 1.72 ± 0.02
BMI (kg �m-2) 23.5 ± 0.9 22.8 ± 0.6
1-RM leg extension (kg) 56 ± 4 64 ± 3
Whole-thigh muscle CSA (mm2) 14,184 ± 462 14,471 ± 386
Quadriceps muscle CSA (mm2) 7,712 ± 324 7,805 ± 221
Data represent mean ± SEM. CON: control; NAD: Nandrolone decanoate; BMI: Body Mass Index; CSA: Cross-
sectional area. 1-RM: one-repetition maximum. Baseline characteristics are not different between groups.
https://doi.org/10.1371/journal.pone.0210823.t001
Nandrolone decanoate does not attenuate disuse muscle loss
PLOS ONE | https://doi.org/10.1371/journal.pone.0210823 January 28, 2019 5 / 15
Subsequently, a serum blood sample was taken from the antecubital vein by venapuncture.
Thereafter, a muscle biopsy was collected from the vastus lateralis muscle of the leg identified as
the leg to become immobilized (or the previously immobilized leg in the case of the second
visit). Muscle biopsy samples were obtained from the middle region of the vastus lateralis, ~1–3
cm below the level that the CT scan was performed, and ~3 cm below entry through the fascia,
by using the percutaneous needle biopsy technique [37]. Any visible non-muscle tissue was
removed immediately, and part of the biopsy sample was embedded in Tissue-Tec (Sakura Fine-
tek, Zoeterwoude, The Netherlands) before being frozen in liquid nitrogen-cooled isopentane,
while another part was immediately frozen in liquid nitrogen. Muscle samples were subsequently
stored at -80˚C until further analyses. Thereafter, subjects’ single-leg 1-RM was assessed. The
estimations obtained during the screening visit were used to determine 1-RM leg strength [35].
Blood analyses
Serum was collected in SST containing tubes (SSTTM Tube with Silica Clot Activator), allowed
to clot for at least 30 min in vertical position at room temperature and then centrifuged at
1550g and 4˚C for 15 min. Aliquots of serum were frozen in liquid nitrogen and stored at –
80˚C until analysis.
Total nandrolone and total testosterone (T) were measured by Liquid Chromatography/
Tandem Mass Spectrometry (LC/MS/MS). CVs of quality control (QC) samples were <10%.
Sex hormone-binding globulin (SHBG) was measured by electrochemiluminescence immuno-
assay (ECLIA) (Roche Diagnostics GmbH, Mannheim, Germany) using the COBAS 8000
modular system. CVs of QC samples were <20%.
Immunohistochemistry
Frozen muscle biopsies were cut into 5 μm thick cryosections using a cryostat at -20˚C, and
thaw mounted on uncoated pre-cleaned glass slides. Samples from pre- and post-immobiliza-
tion were mounted together on the same glass slide. Care was taken to properly align the sam-
ples for cross-sectional fiber analyses. Muscle biopsies were stained to assess muscle fiber type
distribution and CSA, as described previously [38].
Images were visualized and automatically captured at 10x magnification with a fluorescent
microscope equipped with an automatic stage (IX81 motorized inverted microscope; Olym-
pus, Hamburg, Germany) EXi Aqua CCD camera (Q Imaging, Surrey, Canada). Microman-
ager 1.4 software was used for image acquisition [39]. Quantitative analyses were carried out
using Image J software package (version 1.45d, National Institute of Health, USA; [36]). All
image recordings and analyses were performed by an investigator blinded to subject coding.
Mean muscle fiber CSA was calculated for the type I and type II muscle fibers separately.
Mean numbers of 115 ± 12 and 175 ± 16 fibers were analyzed in pre- and post-immobilization
samples, respectively.
Statistics
All data are expressed as mean ± SEM. Per protocol analyses were performed. Baseline values
between groups were compared by means of an independent samples t-test. Primary outcome
parameter was quadriceps CSA. Secondary outcome parameters were leg strength and type I
and II muscle fiber size. Pre- versus post-immobilization data were analyzed using repeated-
measures ANOVA with treatment (CON vs NAD) as between-subject factor and time (pre- vs
post-immobilization) as within-subject factor. A P-value of<0.05 was used to determine sta-
tistical significance. All data were analyzed using IBM SPSS Statistics (version 25, IBM Corp.,
Armonk, USA).
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Results
Subjects and dietary intake
Subjects’ characteristics are provided in Table 1. No differences were observed for age, height,
weight, BMI, whole thigh, and quadriceps CSA and leg strength between the CON and NAD
groups at baseline. Data from the CON group have been published previously (NIH Clinical
Trial Registration Number: NCT01894737) [33]. Two subjects from CON withdrew prior to
immobilization due to time constraints. Table 2 presents data of subjects’ habitual diet under
free-living conditions and during single-leg immobilization. No differences in habitual diet
were observed between groups (all measured parameters P>0.05). Habitual diet did not
change following immobilization in either group (P>0.05). Habitual protein intake averaged
1.2 ± 0.1 and 1.4 ± 0.1 g�kg-1�day-1 in the CON and NAD group, respectively, with no changes
following immobilization (P>0.05).
Muscle mass and leg strength
Quadriceps muscle CSAs are displayed in Fig 2A. At baseline, no differences were observed in
quadriceps muscle CSA between groups (P = 0.59). Seven days of immobilization caused a signifi-
cant reduction in quadriceps muscle CSA (from 7,712 ± 324 mm2 to 7,287 ± 305 mm2 and from
7,805 ± 221 mm2 to 7,352 ± 202 mm2 in the CON and NAD group, respectively (time P<0.01).
No differences were observed in muscle loss between CON (-5.5 ± 0.8%) and NAD (-5.8 ± 0.7%;
P>0.05). Fig 2B shows the individual changes in quadriceps CSA following 7 days of one-legged
knee immobilization. Leg strength data are presented in Fig 3A. Maximal leg strength decreased
following immobilization from 56 ± 4 kg to 53 ± 4 kg (-5.6 ± 2.2%) and from 64 ± 3 kg to 60 ± 3
kg (-6.9 ± 2.6%) in the CON and NAD group, respectively (main effect of time, P<0.05), with no
differences between groups (time × treatment interaction, P = 0.55). Fig 3B shows the individual
changes in maximal leg strength following 7 days of one-legged knee immobilization.
Blood analyses
In general serum nandrolone concentrations are not detectable below levels of 0.01 nmol/L in
healthy men [40]. At baseline and in the CON group also during immobilization, we have not
measured levels above this detection limit. In the NAD group, after injection, serum nandro-
lone concentrations increased to 13.8 ± 1.0 nmol/L during the immobilization period. As
expected, total testosterone concentrations decreased in the NAD group (from 22.2 ± 7.4 to
1.5 ± 1.7 nmol/L) and did not change in the CON group (20.8 ± 5.1 and 20.6 ± 4.8 nmol/L),
pre- and post-immobilization, respectively (time × treatment interaction, P<0.001). The
Table 2. Habitual dietary intake characteristics during free living and immobilization, with (NAD) or without (CON) nandrolone decanoate supplementation.
CON (n = 13) NAD (n = 9)
Free living Immobilization Free living Immobilization
Energy intake (MJ � day-1) 7.6 ± 0.4 7.4 ± 0.6 8.8 ± 0.8 8.5 ± 0.8
Protein (g � kg-1 � day-1) 1.2 ± 0.1 1.1 ± 0.1 1.4 ± 0.1 1.3 ± 0.1
Protein (En%) 19 ± 1 18 ± 1 19 ± 1 20 ± 1
Fat (En%) 31 ± 2 31 ± 3 46 ± 3 49 ± 3
Carbohydrate (En%) 54 ± 8 47 ± 3 34 ± 4 29 ± 3
Data represent mean ± SEM. CON: control; NAD: Nandrolone decanoate. En%: Energy %. Data were analyzed using repeated-measures ANOVA. No differences
between leucine and control were found over time.
https://doi.org/10.1371/journal.pone.0210823.t002
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concentration of SHBG did not differ at baseline (32 ± 2 and 32 ± 3 nmol/L; P = 0.927) and
did not change following immobilization (31 ± 2 and 31 ± 3 nmol/L for CON and NAD,
respectively (P>0.05).
Muscle fiber characteristics
Muscle fiber characteristics are displayed in Table 3. At baseline, no significant differences
between groups were observed for any of the variables. No changes in type I and type II muscle
Fig 2. 2A: Cross-sectional area (CSA) of quadriceps muscle in the CON and NAD group, before and after 7 days of leg
immobilization, as measured by single-slice CT scan. 2B: Individual changes in quadriceps muscle CSA following 7
days of one-legged knee immobilization. Data were analyzed using repeated-measures ANOVA. Data are expressed as
mean±SEM. Immobilization resulted in a significant decline in quadriceps muscle CSA in both groups (� P<0.05),
with no differences between groups.
https://doi.org/10.1371/journal.pone.0210823.g002
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fiber CSA or distribution were observed following immobilization (P>0.05), and no differ-
ences were observed between groups (P>0.05).
Discussion
In the present study, we demonstrated that a single intramuscular injection of nandrolone
decanoate (200 mg) does not attenuate the decline in muscle mass and strength during 7 days
of subsequent leg immobilization in healthy male adults.
A prolonged period of skeletal muscle disuse or short, successive episodes of muscle disuse
can strongly reduce skeletal muscle mass and strength and cause numerous negative health
Fig 3. 3A: Leg muscle strength as measured by one-repetition maximum (1-RM), in the CON and NAD group before
and after 7 days of one-legged knee immobilization. 3B: Individual changes in 1-RM leg muscle strength following 7
days of one-legged knee immobilization. Data were analyzed using repeated-measures ANOVA. Data are expressed as
mean±SEM. Immobilization resulted in a significant decline in muscle strength in both groups (� P<0.05), with no
differences between groups.
https://doi.org/10.1371/journal.pone.0210823.g003
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outcomes [41–45]. It is now believed that short, successive periods of muscle disuse due to
injury or disease may be largely responsible for the progressive loss of skeletal muscle mass
observed throughout the lifespan [1, 4]. In the present study, we observed that 7 days of leg
immobilization causes substantial loss of muscle mass (see Fig 2A). The ~6% decline in quadri-
ceps cross-sectional area was accompanied by a similar (6–7%) decline in leg muscle strength.
These observations are in line with recent data from our group [3, 12] as well as others [46]
reporting a 2–8 and 8–23% decline in muscle mass and strength, respectively, following 1–2
weeks of disuse in both young and older individuals. These data are of important clinical rele-
vance as hospitalization following acute illness or injury is generally accompanied by an aver-
age hospital stay of 6–7 days [2]. The loss of muscle mass and strength during such short
(successive) periods of muscle disuse impairs functional capacity, increases the risk of develop-
ing chronic metabolic disease, and hinders the subsequent rehabilitation upon discharge [47].
Clearly, effective interventional strategies are needed to prevent or attenuate muscle mass and
strength loss during short periods of muscle disuse due to injury, disease, and/or surgery.
Administration of the anabolic androgenic steroid nandrolone has previously been shown
to increase fat free mass, muscle cross-sectional area, and/or strength in several pathological
conditions when applied for 1–6 months with doses ranging between 200–2400 mg [20–30].
Furthermore, nandrolone decanoate administration in healthy men has been shown to increase
fat-free mass and muscle size and strength, especially when combined with resistance type exer-
cise training [48]. In the present study, we administered a single intramuscular 200 mg dose of
nandrolone decanoate immediately prior to immobilization. The injection was well received
and no adverse events were reported following nandrolone decanoate administration during
the subsequent immobilization period. Serum nandrolone concentrations significantly
increased in the NAD group up to 6.0 ng/mL which agrees well with the peak of 5.2 ng/mL after
an intramuscular injection of 150 mg in healthy men in a pharmacokinetic evaluation study of
different doses of nandrolone decanoate [14]. In addition, our increase in nandrolone concen-
trations and decrease in total testosterone concentrations from 6.4 to 0.4 ng/mL are approxi-
mately double the concentrations that were found a week after subcutaneous injection of half of
our dose, i.e. 100 mg nandrolone decanoate in another pharmacokinetic-pharmacodynamic
study [49]. In short, our intervention was quite effective in increasing nandrolone decanoate
concentrations and in line with previous observations. Despite the substantial increase in serum
nandrolone concentrations, no differences were observed in the loss of muscle mass and/or
strength between the NAD and CON group following single leg immobilization.
Although quadriceps CSA declined by 6±1% in response to immobilization in both groups,
such changes were not yet evident on the muscle fiber level. The lack of measurable declines in
Table 3. Muscle fiber characteristics of healthy young men before (pre) and after (post) 7 days of leg immobilization, with (NAD) or without (CON) nandrolone
decanoate supplementation.
CON (n = 13) NAD (n = 15)
Fiber type Pre Post Pre Post
Muscle fiber CSA (μm2) (μm2) I 6034 ± 501 6620 ± 508 6014 ± 283 6188 ± 253
II� 7202 ± 640 7540 ± 587 6587 ± 512 6594 ± 311
% Fiber I 38 ± 4 33 ± 3 40 ± 3 40 ± 4
II� 62 ± 4 67 ± 3 60 ± 3 60 ± 4
Data represent mean ± SEM. Abbreviations: CON: control; NAD: Nandrolone decanoate; CSA: Cross-sectional area. No interaction or time effect was found in any of
the variables.
� Muscle fiber CSA and fiber type distribution (in %) were different between type I and type II muscle fibers on all time points.
https://doi.org/10.1371/journal.pone.0210823.t003
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type I or type II muscle fiber CSA are in line with previous publications investigating changes
in muscle fiber characteristics following a relative short (~7 days) period of physical inactivity
[12, 34], and is attributed to the large variance in fiber size between fibers.
In the present study, we chose to provide nandrolone decanoate on the day of immobiliza-
tion (as opposed to several days or weeks prior to bed rest or immobilization) as it presents a
practical and clinically relevant strategy for more clinically compromised patients being hospi-
talized following both acute injury as well as scheduled surgery. A previous study on nandro-
lone decanoate pharmacokinetics has shown serum nandrolone levels to peak 72 hours after
intramuscular injection, with the half-life of 7–12 days [14]. In agreement, circulating nandro-
lone levels were elevated substantially throughout the 7 days of disuse. Nonetheless, we failed
to detect any impact of nandrolone decanoate administration on muscle mass or strength loss
during single-leg limb immobilization. We can only speculate on the efficacy of higher doses
of nandrolone decanoate or nandrolone decanoate administration in the weeks prior to the
onset of disuse. The latter would be of interest but only applicable for those patients with elec-
tive, planned surgery. Clearly, the proposed benefits of nandrolone decanoate on preventing
or attenuating muscle mass and strength loss during disuse are not as evident as anticipated.
The present study shows that nandrolone decanoate administration does not represent an
effective adjuvant pharmaceutical strategy to prevent or attenuate muscle disuse atrophy.
Prior work from our group has shown that preservation of muscle mass during disuse is
possible by applying exercise mimetics such as neuromuscular electrical stimulation. Daily
application of neuromuscular electrical stimulation was shown to preserve muscle mass in a
leg immobilization model in healthy volunteers [34] as well as in comatose patients in an
intensive care unit setting [50]. It could be speculated that local muscle contraction is required
to allow preservation of skeletal muscle mass and function. It could be speculated that nandro-
lone decanoate could support preservation of muscle mass and/or strength when applied in
combination with exercise (mimetics). The latter is supported by the observation that nandro-
lone decanoate administration has been shown to be (more) potent to support muscle hyper-
trophy when combined with (prolonged) resistance type exercise training [48]. Adjuvant
pharmacological support with nandrolone decanoate may be (more) supportive when com-
bined with exercise (mimetics) during disuse or rather to augment muscle mass and strength
gains during the subsequent rehabilitation process [24, 27, 28, 32]. Therefore, future work
should evaluate the potential benefits of NAD treatment when combined with exercise or exer-
cise mimetics applied during hospitalization and/or subsequent rehabilitation following a
period of disuse. Furthermore, dose response studies should evaluate the impact of timing and
dosing of nandrolone decanoate under such conditions.
Conclusions
Administration of a single bolus of nandrolone decanoate (200 mg) prior to a short period of
disuse does not attenuate muscle mass or strength loss. This is the first study to report no pres-
ervation of skeletal muscle mass and strength following nandrolone decanoate administration
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